Thursday, 15 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· February 26, 2026

Bitcoin Critic David Stockman Gets Reality Check After Popular Analyst Likens BTC Slump To Drawdowns In 'Trillion Dollar Stocks' Like Nvidia, Amazon

View original at finance.yahoo.com
Bitcoin Critic David Stockman Gets Reality Check After Popular Analyst Likens BTC Slump To Drawdowns In 'Trillion Dollar Stocks' Like Nvidia, Amazon Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Bitcoiners might be loving this store of value performance

    80% confidence

  • Rad AI's technology helps transform data chaos into actionable insights and high-performing content with measurable ROI

    80% confidence

  • Bitcoin dropped 48% from record highs to $65,000 in just four months, questioning its store of value narrative

    80% confidence

  • Paladin's ESS uses non-lithium, solid-state graphene battery technology designed for durability, safety, and long service life

    80% confidence

  • Elf Labs valuation growth exceeded 1,600% in under two years

    80% confidence

  • Atari Hotel Phoenix targets 15% preferred return and projected 5.8x multiple for investors

    80% confidence

  • Trillion-dollar stocks like Nvidia and Amazon experienced similar drawdowns and should never have a place in wealth portfolio if same standard applied to Bitcoin

    80% confidence

  • Bitcoin network functions as a global ledger for value transfer

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com